Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers

NCT04666012 is registered in ClinicalTrials.gov with Cellid Co., Ltd. as lead sponsor.

NCT NCT04666012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04666012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
Lead sponsor
Cellid Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
December 29, 2020
Completion date
March 27, 2023
Enrollment
150 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19